Joseph P M, O'Sullivan B P, Lapey A, Dorkin H, Oren J, Balfour R, Perricone M A, Rosenberg M, Wadsworth S C, Smith A E, St George J A, Meeker D P
Cystic Fibrosis Center, Massachusetts General Hospital, Boston 02114, USA.
Hum Gene Ther. 2001 Jul 20;12(11):1369-82. doi: 10.1089/104303401750298535.
Cystic fibrosis (CF), an autosomal recessive disorder resulting from mutations in the cystic fibrosis trans-membrane conductance regulator (CFTR) gene, is the most common lethal genetic illness in the Caucasian population. Gene transfer to airway epithelium, using adenoviruses containing normal CFTR cDNA, leads to transient production of CFTR mRNA and, in some studies, to correction of the airway epithelial ion transport defect caused by dysfunctional CFTR. Inflammatory responses to the adenoviral vector have been reported, particularly at high viral titers. We evaluated the effects of adenovirus-mediated CFTR gene transfer to airway epithelium in 36 subjects with CF (34 individuals, 2 of whom received two separate doses of vector), 20 by lobar instillation and 16 by aerosol administration. Doses ranged from 8 x 10(6) to 2.5 x 10(10) infective units (IU), in 0.5-log increments. After lobar administration of low doses there were occasional reports of cough, low-grade temperature, and myalgias. At the highest lobar dose (2.5 x 10(9) IU) two of three patients had transient myalgias, fever, and increased sputum production with obvious infiltrates on CT scan. After aerosol administration there were no significant systemic symptoms until the 2.5 x 10(10) IU dose, when both patients experienced myalgias and fever that resolved within 24 hr. There were no infiltrates seen on chest CT scans in any of the patients in the aerosol administration group. There were no consistent changes in pulmonary function tests or any significant rise in serum IgG or neutralizing antibodies in patients from either group. Serum, sputum, and nasal cytokines, measured before and after vector administration, showed no correlation with adenoviral dose. Gene transfer to lung cells was inefficient and expression was transient. Cells infected with the vector included mononuclear inflammatory cells as well as cuboidal and columnar epithelial cells. In summary, we found no consistent immune response, no evidence of viral shedding, and no consistent change in pulmonary function in response to adenovirus-mediated CFTR gene transfer. At higher doses there was a mild, nonspecific inflammatory response, as evidenced by fevers and myalgias. Overall, vector administration was tolerated but transfer of CFTR cDNA was inefficient and transgene expression was transient for the doses and method of administration used here.
囊性纤维化(CF)是一种常染色体隐性疾病,由囊性纤维化跨膜传导调节因子(CFTR)基因突变引起,是白种人群中最常见的致命性遗传疾病。使用含有正常CFTR cDNA的腺病毒将基因转移至气道上皮,可导致CFTR mRNA的短暂产生,并且在一些研究中,可纠正由功能失调的CFTR引起的气道上皮离子转运缺陷。已有报道称对腺病毒载体存在炎症反应,尤其是在高病毒滴度时。我们评估了腺病毒介导的CFTR基因转移至36例CF患者(34名个体,其中2名接受了两剂单独的载体)气道上皮的效果,20例通过肺叶滴注,16例通过气雾剂给药。剂量范围为8×10⁶至2.5×10¹⁰感染单位(IU),以0.5对数递增。肺叶给予低剂量后,偶尔有咳嗽、低热和肌痛的报告。在最高肺叶剂量(2.5×10⁹ IU)时,三名患者中有两名出现短暂肌痛、发热,痰液分泌增加,CT扫描有明显浸润。气雾剂给药后,直到2.5×10¹⁰ IU剂量时才出现明显的全身症状,此时两名患者均出现肌痛和发热,在24小时内缓解。气雾剂给药组的任何患者胸部CT扫描均未见浸润。两组患者的肺功能测试均无一致变化,血清IgG或中和抗体也无显著升高。在载体给药前后测量的血清、痰液和鼻内细胞因子与腺病毒剂量无相关性。基因转移至肺细胞效率低下且表达短暂。感染载体的细胞包括单核炎性细胞以及立方上皮细胞和柱状上皮细胞。总之,我们发现对腺病毒介导的CFTR基因转移没有一致的免疫反应,没有病毒脱落的证据,肺功能也没有一致变化。在较高剂量时,出现了轻度非特异性炎症反应,表现为发热和肌痛。总体而言,载体给药可耐受,但CFTR cDNA的转移效率低下,且对于此处使用的剂量和给药方法,转基因表达是短暂的。